Literature DB >> 24763844

Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal?

Althaf Ansary1, Samuel Ibhanesebhor, Chikkanayakanahalli Manjunatha.   

Abstract

Venlafaxine, a serotonin and norepinephrine reuptake inhibitor, is increasingly used in pregnant women with pre-existing depression who require continued treatment. However, its in uteroeffects on the developing fetus are not clear. Herein, we report the unusual presentation of venlafaxine withdrawal in a female preterm baby of 29 weeks gestation, who presented with myoclonic seizures on her second day of life. The seizures were confirmed using amplitude-integrated electroencephalography, and other possible causes of neonatal seizures were excluded. The baby responded to treatment with phenobarbitone and phenytoin. Magnetic resonance imaging of her brain was unremarkable at corrected gestational age of 39 weeks and 2 days. On follow-up at the corrected age of five months, she was well and developing normally with no further seizures. To the best of our knowledge, this is the first report of seizures in a preterm baby resulting from maternal venlafaxine use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24763844      PMCID: PMC4291954          DOI: 10.11622/smedj.2014061

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  15 in total

1.  Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women.

Authors:  A Hostetter; J C Ritchie; Z N Stowe
Journal:  Biol Psychiatry       Date:  2000-11-15       Impact factor: 13.382

2.  Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.

Authors:  A Einarson; B Fatoye; M Sarkar; S V Lavigne; J Brochu; C Chambers; P Mastroiacovo; A Addis; D Matsui; L Schuler; T R Einarson; G Koren
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

3.  [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy].

Authors:  R A de Moor; L Mourad; J ter Haar; A C Egberts
Journal:  Ned Tijdschr Geneeskd       Date:  2003-07-12

4.  Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis.

Authors:  Emilio J Sanz; Carlos De-las-Cuevas; Anne Kiuru; Andrew Bate; Ralph Edwards
Journal:  Lancet       Date:  2005 Feb 5-11       Impact factor: 79.321

Review 5.  Role of cerebral function monitoring in the newborn.

Authors:  L S de Vries; L Hellström-Westas
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2005-05       Impact factor: 5.747

6.  Normal pattern of the cerebral function monitor trace in term and preterm neonates.

Authors:  E Thornberg; K Thiringer
Journal:  Acta Paediatr Scand       Date:  1990-01

Review 7.  Antidepressants in pregnancy: a review of commonly prescribed medications.

Authors:  Avinash S Patil; Jeffrey A Kuller; Eleanor H J Rhee
Journal:  Obstet Gynecol Surv       Date:  2011-12       Impact factor: 2.347

8.  Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

Authors:  Tim F Oberlander; Shaila Misri; Colleen E Fitzgerald; Xanthoula Kostaras; Dan Rurak; Wayne Riggs
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

9.  Reference values for amplitude-integrated electroencephalographic activity in preterm infants younger than 30 weeks' gestational age.

Authors:  Monika Olischar; Katrin Klebermass; Stefan Kuhle; Margot Hulek; Christina Kohlhauser; Ernst Rücklinger; Arnold Pollak; Manfred Weninger
Journal:  Pediatrics       Date:  2004-01       Impact factor: 7.124

10.  Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

Authors:  Rachel Levinson-Castiel; Paul Merlob; Nehama Linder; Lea Sirota; Gil Klinger
Journal:  Arch Pediatr Adolesc Med       Date:  2006-02
View more
  1 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.